[10-Q] UNITEDHEALTH GROUP INC Quarterly Earnings Report
Filing Impact
Filing Sentiment
Form Type
10-Q
Rhea-AI Filing Summary
UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.
Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.
Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.
UnitedHealth Group (UNH) ha riportato i risultati del Q3 2025 che mostrano una forte crescita del top line ma una redditività significativamente inferiore. Le entrate totali sono state $113,2 miliardi, in crescita del 12% anno su anno, trainate dalla crescita di Medicare Advantage e dal volume Optum Rx. L'EPS diluito è stato $2,59 rispetto a $6,51 l'anno precedente poiché i costi sanitari sono aumentati più rapidamente dei premi.
Ridotta redditività: il rapporto di spesa medica è salito all'89,9% dall'85,2%, riflettendo riduzioni di finanziamento Medicare, maggiore utilizzo delle cure e impatti stagionali a seguito dell'Inflation Reduction Act sul Part D. Il margine operativo è sceso al 3,8% dal 8,6% e gli utili operativi sono diminuiti del 50% a $4,3 miliardi.
Andamenti per segmento: i ricavi di UnitedHealthcare sono cresciuti del 16% con 795.000 persone serve in più, principalmente nel Medicare Advantage. Optum ricavi sono aumentati dell'8% (Optum Rx 16%), mentre la redditività di Optum Health è stata pressionata dalle dinamiche Medicare e da tendenze di costo elevate. Nei nove mesi, i flussi di cassa operativi sono stati di $18,6 miliardi, a sostegno dei dividendi e dei riacquisti annunciati nel periodo.
UnitedHealth Group (UNH) informó resultados del tercer trimestre de 2025 mostrando un fuerte crecimiento de ingresos, pero una rentabilidad significativamente menor. Los ingresos totales fueron de $113,2 mil millones, con un crecimiento del 12% interanual, impulsados por el crecimiento de Medicare Advantage y el volumen de Optum Rx. El BPA diluido fue de $2,59 frente a $6,51 hace un año, ya que los costos médicos aumentaron más rápido que las primas.
Rentabilidad comprimida: el índice de costos médicos aumentó al 89,9% desde el 85,2%, reflejando reducciones de financiamiento de Medicare, mayor utilización de cuidados y impactos estacionales del Inflation Reduction Act sobre el Part D. El margen operativo cayó al 3,8% desde el 8,6% y las ganancias de operaciones cayeron un 50% a $4,3 mil millones.
Tendencias por segmento: los ingresos de UnitedHealthcare crecieron un 16% con 795.000 personas más atendidas, principalmente en Medicare Advantage. Los ingresos de Optum subieron un 8% (Optum Rx subió un 16%), mientras que la rentabilidad de Optum Health estuvo presionada por la dinámica de Medicare y las tendencias de costos elevados. En los nueve meses, los flujos de efectivo de operaciones fueron de $18,6 mil millones, respaldando dividendos y recompras anunciados durante el periodo.
UnitedHealth Group (UNH)가 2025년 3분기 실적을 발표 강한 매출 성장에도 불구하고 수익성은 크게 낮아졌습니다. 총매출은 1,132억 달러로 전년비 12% 증가했으며 Medicare Advantage의 성장과 Optum Rx의 거래량이 이를 견인했습니다. 희석주당순이익(EPS)은 2.59달러로, 전년동기의 6.51달러에 비해 감소했는데, 의료비가 보험료보다 빠르게 증가했습니다.
수익성 축소: 의료비 비율은 89.9%로 85.2%에서 상승했습니다. 이는 Medicare 자금 지원의 감소, 증가하는 진료 이용, Inflation Reduction Act가 Part D에 미친 계절적 영향 때문입니다. 영업이익률은 8.6%에서 3.8%로 하락했고 영업이익은 50% 감소한 43억 달러였습니다.
세그먼트 동향: UnitedHealthcare 매출은 16% 증가했으며 79만 5천 명의 더 많은 고객이 서비스 받았습니다, 주로 Medicare Advantage에서. Optum 매출은 8% 상승(Optum Rx 16% 상승), 반면 Optum Health의 수익성은 Medicare의 역학과 높은 비용 추세로 압박을 받았습니다. 9개월 동안 영업현금흐름은 186억 달러로 배당금 및 기간 중 공시된 자사주 매입을 지원했습니다.
UnitedHealth Group (UNH) a annoncé les résultats du T3 2025 montrant une forte croissance du chiffre d'affaires mais une rentabilité nettement plus faible. Les revenus totaux se sont élevés à 113,2 milliards de dollars, en hausse de 12% d'une année sur l'autre, soutenus par la croissance de Medicare Advantage et le volume Optum Rx. L'EPS dilué s'établit à 2,59 dollars contre 6,51 dollars l'année précédente, car les coûts médicaux ont augmenté plus rapidement que les primes.
Rentabilité comprimée: le ratio des coûts médicaux a augmenté à 89,9% contre 85,2%, reflétant les réductions de financement de Medicare, une utilisation accrue des soins et les effets saisonniers de la Inflation Reduction Act sur le Part D. La marge opérationnelle est tombée à 3,8% contre 8,6% et le résultat des opérations a diminué de 50% à 4,3 milliards de dollars.
Tendances par segment: les revenus d'UnitedHealthcare ont augmenté de 16% avec 795 000 personnes de plus desservies, principalement dans Medicare Advantage. Les revenus d'Optum ont augmenté de 8% (Optum Rx de 16%), tandis que la rentabilité d'Optum Health a été sous pression en raison de la dynamique de Medicare et de coûts élevés. Pour les neuf mois, les flux de trésorerie opérationnels s'élevaient à 18,6 milliards de dollars, soutenant les dividendes et les rachats annoncés durant la période.
UnitedHealth Group (UNH) meldete Ergebnisse für Q3 2025 mit starkem Umsatzwachstum, aber deutlich geringerer Rentabilität. Die Gesamteinnahmen betrugen 113,2 Milliarden US-Dollar, ein Anstieg von 12% im Jahresvergleich, getrieben durch Medicare Advantage-Wachstum und Optum Rx-Volumen. Diluted EPS betrug 2,59 USD gegenüber 6,51 USD vor einem Jahr, da die medizinischen Kosten schneller als die Prämien stiegen.
Profitabilität komprimiert: Die medizinische Kostenquote stieg von 85,2% auf 89,9%, was auf Kürzungen der Medicare-Finanzierung, höhere Behandlungsauslastung und saisonale Effekte des Inflation Reduction Act auf Part D zurückzuführen ist. Die operative Marge fiel von 8,6% auf 3,8% und die operativen Erträge sanken um 50% auf 4,3 Milliarden USD.
Segmenttrends: Der Umsatz von UnitedHealthcare wuchs um 16% und 795.000 zusätzliche Personen wurden bedient, vor allem im Medicare Advantage. Optum-Umsätze stiegen um 8% (Optum Rx +16%), während die Rentabilität von Optum Health durch Medicare-Dynamik und steigende Kosten belastet wurde. In den ersten neun Monaten betrugen die operativen Cashflows 18,6 Milliarden USD, was die laufenden Dividenden und Aktienrückkäufe deckt, die im Zeitraum bekannt gegeben wurden.
أعلنت مجموعة UnitedHealth Group (UNH) عن نتائج الربع الثالث 2025 مع نمو قوي في الإيرادات الإجمالية لكن ربحية أقل بشكل ملحوظ. بلغت الإيرادات الإجمالية 113.2 مليار دولار، بارتفاع 12% على أساس سنوي، مدعومة بنمو Medicare Advantage وحجم Optum Rx. كان ربح السهم المخفف 2.59 دولار مقابل 6.51 دولار قبل عام، حيث ارتفعت تكاليف الرعاية الطبية أسرع من الأقساط.
الربحية مضغوطة: ارتفع معامل تكلفة الرعاية الطبية إلى 89.9% من 85.2%، مع انعكاس تقليص تمويل Medicare، وزيادة استخدام الرعاية، وتأثيرات موسمية من Inflation Reduction Act على Part D. هبط هامش التشغيل إلى 3.8% من 8.6% وتراجعت الأرباح من العمليات بنسبة 50% إلى 4.3 مليار دولار.
الاتجاهات حسب القطاعات: ارتفعت إيرادات UnitedHealthcare بنسبة 16% مع خدمة 795,000 شخص إضافي، ويرجع ذلك أساساً إلى Medicare Advantage. ارتفعت إيرادات Optum بنسبة 8% (Optum Rx بنسبة 16%)، بينما تضررت ربحية Optum Health بسبب ديناميكيات Medicare واتجاهات التكاليف المرتفعة. خلال التسعة أشهر، بلغت التدفقات النقدية من العمليات 18.6 مليار دولار، داعمة للأرباح الموزعة وإعادة شراء الأسهم كما ورد في الفترة.
Positive
- None.
Negative
- Operating earnings fell 50% to $4.3B in Q3 2025.
- Medical care ratio increased 470 bps to 89.9%, pressuring margins.
- Diluted EPS declined to $2.59 from $6.51 year over year.
Insights
Revenue rose, but margins compressed sharply on higher medical costs.
UNH delivered Q3 revenue of
Segment mix mattered: UnitedHealthcare revenue grew
Cash generation remained solid with year-to-date operating cash flow of
UnitedHealth Group (UNH) ha riportato i risultati del Q3 2025 che mostrano una forte crescita del top line ma una redditività significativamente inferiore. Le entrate totali sono state $113,2 miliardi, in crescita del 12% anno su anno, trainate dalla crescita di Medicare Advantage e dal volume Optum Rx. L'EPS diluito è stato $2,59 rispetto a $6,51 l'anno precedente poiché i costi sanitari sono aumentati più rapidamente dei premi.
Ridotta redditività: il rapporto di spesa medica è salito all'89,9% dall'85,2%, riflettendo riduzioni di finanziamento Medicare, maggiore utilizzo delle cure e impatti stagionali a seguito dell'Inflation Reduction Act sul Part D. Il margine operativo è sceso al 3,8% dal 8,6% e gli utili operativi sono diminuiti del 50% a $4,3 miliardi.
Andamenti per segmento: i ricavi di UnitedHealthcare sono cresciuti del 16% con 795.000 persone serve in più, principalmente nel Medicare Advantage. Optum ricavi sono aumentati dell'8% (Optum Rx 16%), mentre la redditività di Optum Health è stata pressionata dalle dinamiche Medicare e da tendenze di costo elevate. Nei nove mesi, i flussi di cassa operativi sono stati di $18,6 miliardi, a sostegno dei dividendi e dei riacquisti annunciati nel periodo.
UnitedHealth Group (UNH) informó resultados del tercer trimestre de 2025 mostrando un fuerte crecimiento de ingresos, pero una rentabilidad significativamente menor. Los ingresos totales fueron de $113,2 mil millones, con un crecimiento del 12% interanual, impulsados por el crecimiento de Medicare Advantage y el volumen de Optum Rx. El BPA diluido fue de $2,59 frente a $6,51 hace un año, ya que los costos médicos aumentaron más rápido que las primas.
Rentabilidad comprimida: el índice de costos médicos aumentó al 89,9% desde el 85,2%, reflejando reducciones de financiamiento de Medicare, mayor utilización de cuidados y impactos estacionales del Inflation Reduction Act sobre el Part D. El margen operativo cayó al 3,8% desde el 8,6% y las ganancias de operaciones cayeron un 50% a $4,3 mil millones.
Tendencias por segmento: los ingresos de UnitedHealthcare crecieron un 16% con 795.000 personas más atendidas, principalmente en Medicare Advantage. Los ingresos de Optum subieron un 8% (Optum Rx subió un 16%), mientras que la rentabilidad de Optum Health estuvo presionada por la dinámica de Medicare y las tendencias de costos elevados. En los nueve meses, los flujos de efectivo de operaciones fueron de $18,6 mil millones, respaldando dividendos y recompras anunciados durante el periodo.
UnitedHealth Group (UNH)가 2025년 3분기 실적을 발표 강한 매출 성장에도 불구하고 수익성은 크게 낮아졌습니다. 총매출은 1,132억 달러로 전년비 12% 증가했으며 Medicare Advantage의 성장과 Optum Rx의 거래량이 이를 견인했습니다. 희석주당순이익(EPS)은 2.59달러로, 전년동기의 6.51달러에 비해 감소했는데, 의료비가 보험료보다 빠르게 증가했습니다.
수익성 축소: 의료비 비율은 89.9%로 85.2%에서 상승했습니다. 이는 Medicare 자금 지원의 감소, 증가하는 진료 이용, Inflation Reduction Act가 Part D에 미친 계절적 영향 때문입니다. 영업이익률은 8.6%에서 3.8%로 하락했고 영업이익은 50% 감소한 43억 달러였습니다.
세그먼트 동향: UnitedHealthcare 매출은 16% 증가했으며 79만 5천 명의 더 많은 고객이 서비스 받았습니다, 주로 Medicare Advantage에서. Optum 매출은 8% 상승(Optum Rx 16% 상승), 반면 Optum Health의 수익성은 Medicare의 역학과 높은 비용 추세로 압박을 받았습니다. 9개월 동안 영업현금흐름은 186억 달러로 배당금 및 기간 중 공시된 자사주 매입을 지원했습니다.
UnitedHealth Group (UNH) a annoncé les résultats du T3 2025 montrant une forte croissance du chiffre d'affaires mais une rentabilité nettement plus faible. Les revenus totaux se sont élevés à 113,2 milliards de dollars, en hausse de 12% d'une année sur l'autre, soutenus par la croissance de Medicare Advantage et le volume Optum Rx. L'EPS dilué s'établit à 2,59 dollars contre 6,51 dollars l'année précédente, car les coûts médicaux ont augmenté plus rapidement que les primes.
Rentabilité comprimée: le ratio des coûts médicaux a augmenté à 89,9% contre 85,2%, reflétant les réductions de financement de Medicare, une utilisation accrue des soins et les effets saisonniers de la Inflation Reduction Act sur le Part D. La marge opérationnelle est tombée à 3,8% contre 8,6% et le résultat des opérations a diminué de 50% à 4,3 milliards de dollars.
Tendances par segment: les revenus d'UnitedHealthcare ont augmenté de 16% avec 795 000 personnes de plus desservies, principalement dans Medicare Advantage. Les revenus d'Optum ont augmenté de 8% (Optum Rx de 16%), tandis que la rentabilité d'Optum Health a été sous pression en raison de la dynamique de Medicare et de coûts élevés. Pour les neuf mois, les flux de trésorerie opérationnels s'élevaient à 18,6 milliards de dollars, soutenant les dividendes et les rachats annoncés durant la période.
UnitedHealth Group (UNH) meldete Ergebnisse für Q3 2025 mit starkem Umsatzwachstum, aber deutlich geringerer Rentabilität. Die Gesamteinnahmen betrugen 113,2 Milliarden US-Dollar, ein Anstieg von 12% im Jahresvergleich, getrieben durch Medicare Advantage-Wachstum und Optum Rx-Volumen. Diluted EPS betrug 2,59 USD gegenüber 6,51 USD vor einem Jahr, da die medizinischen Kosten schneller als die Prämien stiegen.
Profitabilität komprimiert: Die medizinische Kostenquote stieg von 85,2% auf 89,9%, was auf Kürzungen der Medicare-Finanzierung, höhere Behandlungsauslastung und saisonale Effekte des Inflation Reduction Act auf Part D zurückzuführen ist. Die operative Marge fiel von 8,6% auf 3,8% und die operativen Erträge sanken um 50% auf 4,3 Milliarden USD.
Segmenttrends: Der Umsatz von UnitedHealthcare wuchs um 16% und 795.000 zusätzliche Personen wurden bedient, vor allem im Medicare Advantage. Optum-Umsätze stiegen um 8% (Optum Rx +16%), während die Rentabilität von Optum Health durch Medicare-Dynamik und steigende Kosten belastet wurde. In den ersten neun Monaten betrugen die operativen Cashflows 18,6 Milliarden USD, was die laufenden Dividenden und Aktienrückkäufe deckt, die im Zeitraum bekannt gegeben wurden.
أعلنت مجموعة UnitedHealth Group (UNH) عن نتائج الربع الثالث 2025 مع نمو قوي في الإيرادات الإجمالية لكن ربحية أقل بشكل ملحوظ. بلغت الإيرادات الإجمالية 113.2 مليار دولار، بارتفاع 12% على أساس سنوي، مدعومة بنمو Medicare Advantage وحجم Optum Rx. كان ربح السهم المخفف 2.59 دولار مقابل 6.51 دولار قبل عام، حيث ارتفعت تكاليف الرعاية الطبية أسرع من الأقساط.
الربحية مضغوطة: ارتفع معامل تكلفة الرعاية الطبية إلى 89.9% من 85.2%، مع انعكاس تقليص تمويل Medicare، وزيادة استخدام الرعاية، وتأثيرات موسمية من Inflation Reduction Act على Part D. هبط هامش التشغيل إلى 3.8% من 8.6% وتراجعت الأرباح من العمليات بنسبة 50% إلى 4.3 مليار دولار.
الاتجاهات حسب القطاعات: ارتفعت إيرادات UnitedHealthcare بنسبة 16% مع خدمة 795,000 شخص إضافي، ويرجع ذلك أساساً إلى Medicare Advantage. ارتفعت إيرادات Optum بنسبة 8% (Optum Rx بنسبة 16%)، بينما تضررت ربحية Optum Health بسبب ديناميكيات Medicare واتجاهات التكاليف المرتفعة. خلال التسعة أشهر، بلغت التدفقات النقدية من العمليات 18.6 مليار دولار، داعمة للأرباح الموزعة وإعادة شراء الأسهم كما ورد في الفترة.
UnitedHealth Group (UNH)公布了2025年第三季度业绩，显示出强劲的收入增长，但盈利能力显著下降。总收入为1,132亿美元，同比增长12%，受Medicare Advantage增长和Optum Rx交易量推动。摊薄后每股收益为2.59美元，而一年前为6.51美元，因为医疗成本上涨快于保费。
盈利能力受挤压：医疗成本比率上升至89.9%，高于85.2%，反映了 Medicare 资助减少、医疗需求增加，以及Inflation Reduction Act对 Part D的季节性影响。营业利润率从8.6%降至3.8%，经营利润下降50%至43亿美元。
分部趋势：UnitedHealthcare 的收入增加了16%，有79.5万人次增加受服务，主要来自 Medicare Advantage。Optum 的收入增长8%（Optum Rx 增长16%），而 Optum Health 的盈利能力受到 Medicare 动态和成本上升的压力。九个月期间，经营性现金流为186亿美元，支持该期间披露的持续派息和回购。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
FORM 10-Q
__________________________________________________________
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended September 30, 2025
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________________________
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||||||||||||||
| (Address of principal executive offices) | (Zip Code) | (Address of principal executive offices) | (Zip Code) | |||||||||||||||||||||||
(Registrant’s telephone number, including area code)
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
| ☒ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | |||||||||||||||||||
| Smaller reporting company | Emerging growth company | ||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 24, 2025, there were 905,838,620 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.
UNITEDHEALTH GROUP
Table of Contents
| Page | ||||||||||||||
Part I. Financial Information | ||||||||||||||
Item 1. | Financial Statements (unaudited) | 1 | ||||||||||||
Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 | 1 | |||||||||||||
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 | 2 | |||||||||||||
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 | 3 | |||||||||||||
Condensed Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2025 and 2024 | 4 | |||||||||||||
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 | 6 | |||||||||||||
Notes to the Condensed Consolidated Financial Statements | 7 | |||||||||||||
1. | Basis of Presentation | 7 | ||||||||||||
2. | Investments | 8 | ||||||||||||
3. | Fair Value | 10 | ||||||||||||
4. | Medical Costs Payable | 11 | ||||||||||||
5. | Short-Term Borrowings and Long-Term Debt | 12 | ||||||||||||
6. | Dividends | 12 | ||||||||||||
7. | Commitments and Contingencies | 12 | ||||||||||||
8. | Held for Sale | 13 | ||||||||||||
9. | Business Combinations | 14 | ||||||||||||
10. | Segment Financial Information | 15 | ||||||||||||
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 | ||||||||||||
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 26 | ||||||||||||
Item 4. | Controls and Procedures | 26 | ||||||||||||
Part II. Other Information | ||||||||||||||
Item 1. | Legal Proceedings | 27 | ||||||||||||
Item 1A. | Risk Factors | 27 | ||||||||||||
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 27 | ||||||||||||
Item 5. | Other Information | 27 | ||||||||||||
Item 6. | Exhibits | 28 | ||||||||||||
Signatures | 29 | |||||||||||||
PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
| (in millions, except per share data) | September 30, 2025 | December 31, 2024 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||||
| Short-term investments | ||||||||||||||
| Accounts receivable, net | ||||||||||||||
| Other current receivables, net | ||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
| Long-term investments | ||||||||||||||
| Property, equipment and capitalized software, net | ||||||||||||||
| Goodwill | ||||||||||||||
| Other intangible assets, net | ||||||||||||||
| Other assets | ||||||||||||||
| Total assets | $ | $ | ||||||||||||
| Liabilities, redeemable noncontrolling interests and equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Medical costs payable | $ | $ | ||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||
| Short-term borrowings and current maturities of long-term debt | ||||||||||||||
| Unearned revenues | ||||||||||||||
| Other current liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Long-term debt, less current maturities | ||||||||||||||
| Deferred income taxes | ||||||||||||||
| Other liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
Commitments and contingencies (Note 7) | ||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||
| Equity: | ||||||||||||||
Preferred stock, $ | ||||||||||||||
Common stock, $ | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Accumulated other comprehensive loss | ( | ( | ||||||||||||
| Nonredeemable noncontrolling interests | ||||||||||||||
| Total equity | ||||||||||||||
| Total liabilities, redeemable noncontrolling interests and equity | $ | $ | ||||||||||||
See Notes to the Condensed Consolidated Financial Statements
1
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| (in millions, except per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Premiums | $ | $ | $ | $ | ||||||||||||||||||||||
| Products | ||||||||||||||||||||||||||
| Services | ||||||||||||||||||||||||||
| Investment and other income | ||||||||||||||||||||||||||
| Total revenues | ||||||||||||||||||||||||||
| Operating costs: | ||||||||||||||||||||||||||
| Medical costs | ||||||||||||||||||||||||||
| Operating costs | ||||||||||||||||||||||||||
| Cost of products sold | ||||||||||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||||||||
| Total operating costs | ||||||||||||||||||||||||||
| Earnings from operations | ||||||||||||||||||||||||||
| Interest expense | ( | ( | ( | ( | ||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ( | ( | ( | ( | ||||||||||||||||||||||
| Earnings before income taxes | ||||||||||||||||||||||||||
| Provision for income taxes | ( | ( | ( | ( | ||||||||||||||||||||||
| Net earnings | ||||||||||||||||||||||||||
| Earnings attributable to noncontrolling interests | ( | ( | ( | ( | ||||||||||||||||||||||
| Net earnings attributable to UnitedHealth Group common shareholders | $ | $ | $ | $ | ||||||||||||||||||||||
| Earnings per share attributable to UnitedHealth Group common shareholders: | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ||||||||||||||||||||||
| Basic weighted-average number of common shares outstanding | ||||||||||||||||||||||||||
| Dilutive effect of common share equivalents | ||||||||||||||||||||||||||
| Diluted weighted-average number of common shares outstanding | ||||||||||||||||||||||||||
| Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | ||||||||||||||||||||||||||
See Notes to the Condensed Consolidated Financial Statements
2
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Net earnings | $ | $ | $ | $ | ||||||||||||||||||||||
| Other comprehensive income: | ||||||||||||||||||||||||||
| Gross unrealized gains on investment securities during the period | ||||||||||||||||||||||||||
| Income tax effect | ( | ( | ( | ( | ||||||||||||||||||||||
| Total unrealized gains, net of tax | ||||||||||||||||||||||||||
| Gross reclassification adjustment for net realized gains included in net earnings | ( | ( | ( | ( | ||||||||||||||||||||||
| Income tax effect | ||||||||||||||||||||||||||
| Total reclassification adjustment, net of tax | ( | ( | ( | ( | ||||||||||||||||||||||
| Foreign currency translation (losses) gains | ( | ( | ||||||||||||||||||||||||
| Reclassification adjustment for translation losses included in net earnings | ||||||||||||||||||||||||||
| Total foreign currency translation (losses) gains | ( | |||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||
| Comprehensive income | ||||||||||||||||||||||||||
| Comprehensive income attributable to noncontrolling interests | ( | ( | ( | ( | ||||||||||||||||||||||
| Comprehensive income attributable to UnitedHealth Group common shareholders | $ | $ | $ | $ | ||||||||||||||||||||||
See Notes to the Condensed Consolidated Financial Statements
3
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
| Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Nonredeemable Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Three months ended September 30, (in millions) | Shares | Amount | Net Unrealized (Losses) Gains on Investments | Foreign Currency Translation (Losses) Gains | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Net earnings | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | ( | |||||||||||||||||||||||||||||||||||||||||||||||||
| Issuances of common stock, and related tax effects | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | ( | |||||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($ | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Redeemable noncontrolling interests fair value and other adjustments | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and other adjustments of nonredeemable noncontrolling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution to nonredeemable noncontrolling interests | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Net earnings | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | ( | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($ | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and other adjustments of nonredeemable noncontrolling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
See Notes to the Condensed Consolidated Financial Statements
4
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
| Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Nonredeemable Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Nine months ended September 30, (in millions) | Shares | Amount | Net Unrealized (Losses) Gains on Investments | Foreign Currency Translation (Losses) Gains | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance at January 1, 2025 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Net earnings | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuances of common stock, and related tax effects | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | ( | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($ | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Redeemable noncontrolling interests fair value and other adjustments | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and other adjustments of nonredeemable noncontrolling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution to nonredeemable noncontrolling interests | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Balance at January 1, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
| Net earnings | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | ( | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($ | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and other adjustments of nonredeemable noncontrolling interests | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||
See Notes to the Condensed Consolidated Financial Statements
5
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended September 30, | ||||||||||||||
| (in millions) | 2025 | 2024 | ||||||||||||
| Operating activities | ||||||||||||||
| Net earnings | $ | $ | ||||||||||||
| Noncash items: | ||||||||||||||
| Depreciation and amortization | ||||||||||||||
| Deferred income taxes | ( | ( | ||||||||||||
| Share-based compensation | ||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ||||||||||||||
| Other, net | ( | |||||||||||||
| Net change in other operating items, net of effects from acquisitions and dispositions: | ||||||||||||||
| Accounts receivable | ||||||||||||||
| Other assets | ( | ( | ||||||||||||
| Medical costs payable | ||||||||||||||
| Accounts payable and other liabilities | ( | |||||||||||||
| Unearned revenues | ( | |||||||||||||
| Cash flows from operating activities | ||||||||||||||
| Investing activities | ||||||||||||||
| Purchases of investments | ( | ( | ||||||||||||
| Sales of investments | ||||||||||||||
| Maturities of investments | ||||||||||||||
| Cash paid for acquisitions and other transactions, net of cash assumed | ( | ( | ||||||||||||
| Purchases of property, equipment and capitalized software | ( | ( | ||||||||||||
| Loans to care providers - cyberattack | ( | |||||||||||||
| Repayments of care provider loans - cyberattack | ||||||||||||||
| Other, net | ( | ( | ||||||||||||
| Cash flows used for investing activities | ( | ( | ||||||||||||
| Financing activities | ||||||||||||||
| Common share repurchases | ( | ( | ||||||||||||
| Cash dividends paid | ( | ( | ||||||||||||
| Proceeds from common stock issuances | ||||||||||||||
| Repayments of long-term debt | ( | ( | ||||||||||||
| Proceeds from (repayments of) short-term borrowings, net | ( | |||||||||||||
| Proceeds from issuance of long-term debt | ||||||||||||||
| Customer funds administered | ( | ( | ||||||||||||
| Other, net | ( | ( | ||||||||||||
| Cash flows (used for) from financing activities | ( | |||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | |||||||||||||
| Increase in cash and cash equivalents, including cash within businesses held for sale | ||||||||||||||
| Less: net increase in cash within businesses held for sale | ( | ( | ||||||||||||
| Net increase in cash and cash equivalents | ||||||||||||||
| Cash and cash equivalents, beginning of period | ||||||||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||||||||
See Notes to the Condensed Consolidated Financial Statements
6
Table of Contents
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of September 30, 2025 and December 31, 2024, accounts receivable related to products and services were $10.1 billion and $9.9 billion, respectively. As of September 30, 2025, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $11.6 billion, of which approximately half is expected to be recognized in the next three years .
7
Table of Contents
2. Investments
A summary of debt securities by major security type is as follows:
| (in millions) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | ||||||||||||||||||||||
| September 30, 2025 | ||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | $ | $ | ( | $ | |||||||||||||||||||||
| State and municipal obligations | ( | |||||||||||||||||||||||||
| Corporate obligations | ( | |||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ( | |||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ( | |||||||||||||||||||||||||
| Total debt securities - available-for-sale | ( | |||||||||||||||||||||||||
| Debt securities - held-to-maturity: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | ( | |||||||||||||||||||||||||
| State and municipal obligations | ( | |||||||||||||||||||||||||
| Corporate obligations | ||||||||||||||||||||||||||
| Total debt securities - held-to-maturity | ( | |||||||||||||||||||||||||
| Total debt securities | $ | $ | $ | ( | $ | |||||||||||||||||||||
| December 31, 2024 | ||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | $ | $ | ( | $ | |||||||||||||||||||||
| State and municipal obligations | ( | |||||||||||||||||||||||||
| Corporate obligations | ( | |||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ( | |||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ( | |||||||||||||||||||||||||
| Total debt securities - available-for-sale | ( | |||||||||||||||||||||||||
| Debt securities - held-to-maturity: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | ( | |||||||||||||||||||||||||
| State and municipal obligations | ( | |||||||||||||||||||||||||
| Corporate obligations | ||||||||||||||||||||||||||
| Total debt securities - held-to-maturity | ( | |||||||||||||||||||||||||
| Total debt securities | $ | $ | $ | ( | $ | |||||||||||||||||||||
The Company held $5.6 billion and $4.9 billion of equity securities as of September 30, 2025 and December 31, 2024, respectively. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $3.5 billion and $3.8 billion of equity method investments primarily in operating businesses in the health care sector as of September 30, 2025 and December 31, 2024, respectively. The allowance for credit losses on held-to-maturity securities at September 30, 2025 and December 31, 2024 was not material.
8
Table of Contents
The amortized cost and fair value of debt securities as of September 30, 2025, by contractual maturity, were as follows:
| Available-for-Sale | Held-to-Maturity | |||||||||||||||||||||||||
| (in millions) | Amortized Cost | Fair Value | Amortized Cost | Fair Value | ||||||||||||||||||||||
| Due in one year or less | $ | $ | $ | $ | ||||||||||||||||||||||
| Due after one year through five years | ||||||||||||||||||||||||||
| Due after five years through ten years | ||||||||||||||||||||||||||
| Due after ten years | ||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | — | — | ||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | — | — | ||||||||||||||||||||||||
| Total debt securities | $ | $ | $ | $ | ||||||||||||||||||||||
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
| Less Than 12 Months | 12 Months or Greater | Total | ||||||||||||||||||||||||||||||||||||
| (in millions) | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | ||||||||||||||||||||||||||||||||
| September 30, 2025 | ||||||||||||||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | $ | ( | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||||||
| State and municipal obligations | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| Corporate obligations | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ( | ( | ||||||||||||||||||||||||||||||||||||
| Total debt securities - available-for-sale | $ | $ | ( | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||||||
| December 31, 2024 | ||||||||||||||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | $ | ( | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||||||
| State and municipal obligations | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| Corporate obligations | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| Total debt securities - available-for-sale | $ | $ | ( | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||||||
The Company’s unrealized losses from debt securities as of September 30, 2025 were generated from approximately 25,000 positions out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of September 30, 2025, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at September 30, 2025 and December 31, 2024 was not material.
9
Table of Contents
3. Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
| (in millions) | Quoted Prices in Active Markets (Level 1) | Other Observable Inputs (Level 2) | Unobservable Inputs (Level 3) | Total Fair and Carrying Value | ||||||||||||||||||||||
| September 30, 2025 | ||||||||||||||||||||||||||
| Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | ||||||||||||||||||||||||||
| State and municipal obligations | ||||||||||||||||||||||||||
| Corporate obligations | ||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ||||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ||||||||||||||||||||||||||
| Total debt securities - available-for-sale | ||||||||||||||||||||||||||
| Equity securities | ||||||||||||||||||||||||||
| Total assets at fair value | $ | $ | $ | $ | ||||||||||||||||||||||
| Percentage of total assets at fair value | 35 | % | 64 | % | 1 | % | 100 | % | ||||||||||||||||||
| December 31, 2024 | ||||||||||||||||||||||||||
| Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | ||||||||||||||||||||||||||
| State and municipal obligations | ||||||||||||||||||||||||||
| Corporate obligations | ||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | ||||||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | ||||||||||||||||||||||||||
| Total debt securities - available-for-sale | ||||||||||||||||||||||||||
| Equity securities | ||||||||||||||||||||||||||
| Total assets at fair value | $ | $ | $ | $ | ||||||||||||||||||||||
| Percentage of total assets at fair value | 42 | % | 57 | % | 1 | % | 100 | % | ||||||||||||||||||
There were no
10
Table of Contents
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
| (in millions) | Quoted Prices in Active Markets (Level 1) | Other Observable Inputs (Level 2) | Unobservable Inputs (Level 3) | Total Fair Value | Total Carrying Value | |||||||||||||||||||||||||||
| September 30, 2025 | ||||||||||||||||||||||||||||||||
| Debt securities - held-to-maturity | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| Long-term debt and other financing obligations | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| December 31, 2024 | ||||||||||||||||||||||||||||||||
| Debt securities - held-to-maturity | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| Long-term debt and other financing obligations | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of September 30, 2025 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information, market conditions and third-party indications. There were no
4. Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
| (in millions) | 2025 | 2024 | ||||||||||||
| Medical costs payable, beginning of period | $ | $ | ||||||||||||
| Acquisitions (dispositions), net | ( | |||||||||||||
| Reported medical costs: | ||||||||||||||
| Current year | ||||||||||||||
| Prior years | ( | ( | ||||||||||||
| Total reported medical costs | ||||||||||||||
| Medical payments: | ||||||||||||||
| Payments for current year | ( | ( | ||||||||||||
| Payments for prior years | ( | ( | ||||||||||||
| Total medical payments | ( | ( | ||||||||||||
| Less: increase in medical costs payable included within businesses held for sale | ( | ( | ||||||||||||
| Medical costs payable, end of period | $ | $ | ||||||||||||
11
Table of Contents
5. Short-Term Borrowings and Long-Term Debt
In June 2025, the Company issued $3.0 billion of senior unsecured notes consisting of the following:
| (in millions, except percentages) | Par Value | |||||||
| $ | ||||||||
As of September 30, 2025, the Company had $2.9 billion of commercial paper outstanding, with a weighted-average annual interest rate of 4.2 %.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.
6. Dividends
In June 2025, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.84 compared to $8.40 per share, which the Company had paid since June 2024. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s dividend payments during the nine months ended September 30, 2025:
| Payment Date | Amount per Share | Total Amount Paid | ||||||||||||
| (in millions) | ||||||||||||||
| March 18 | $ | $ | ||||||||||||
| June 24 | ||||||||||||||
| September 23 | ||||||||||||||
7. Commitments and Contingencies
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers, shareholders, and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
12
Table of Contents
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General (OIG), the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS and OIG have selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a Special Master appointed by the court issued a report recommending that the court enter summary judgment in the Company’s favor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master’s report. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
8. Held for Sale
The Company’s planned sale of its remaining South American operations continues to progress and is now expected to close in the second half of 2026, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid expenses and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.
The assets and liabilities of the held for sale disposal group as of September 30, 2025, were as follows:
| (in millions) | Businesses Held for Sale | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | |||||||
| Accounts receivable and other current assets | ||||||||
| Property, equipment and capitalized software | ||||||||
| Goodwill and other intangible assets | ||||||||
| Other long-term assets | ||||||||
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1) | ( | |||||||
| Total assets | $ | |||||||
| Liabilities | ||||||||
| Medical costs payable | $ | |||||||
| Accounts payable and other current liabilities | ||||||||
| Other long-term liabilities | ||||||||
| Total liabilities | $ | |||||||
(1) Includes the effect of $985 million of cumulative foreign currency translation losses and $269 million of noncontrolling interests.
13
Table of Contents
9. Business Combinations
During the nine months ended September 30, 2025, the Company completed several business combinations for total consideration of $4.7 billion.
Acquired assets (liabilities) at acquisition date were:
| (in millions) | ||||||||
| Cash and cash equivalents | $ | |||||||
| Accounts receivable and other current assets | ||||||||
| Property, equipment and other long-term assets | ||||||||
| Other intangible assets | ||||||||
| Total identifiable assets acquired | ||||||||
| Medical costs payable | ( | |||||||
| Accounts payable and other current liabilities | ( | |||||||
| Other long-term liabilities | ( | |||||||
| Total identifiable liabilities acquired | ( | |||||||
| Total net identifiable assets | ||||||||
| Goodwill | ||||||||
| Nonredeemable noncontrolling interests | ( | |||||||
| Net assets acquired | $ | |||||||
The majority of goodwill is not deductible for income tax purposes. Goodwill attributable to Optum Health from the business combinations completed was $3.4 billion. The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to intangible assets were:
| (in millions, except years) | Fair Value | Weighted-Average Useful Life | ||||||||||||
| Acquired finite-lived intangible assets: | ||||||||||||||
| Customer-related | $ | |||||||||||||
| Trademarks and technology | ||||||||||||||
| Other | ||||||||||||||
| Total acquired finite-lived intangible assets | ||||||||||||||
| Total acquired indefinite-lived intangible assets - operating licenses and certificates | ||||||||||||||
| Total acquired intangible assets | $ | |||||||||||||
The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through September 30, 2025, acquired entities’ impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the nine months ended September 30, 2025 and 2024, as if the business combinations had occurred on January 1, 2024, were immaterial for both periods.
14
Table of Contents
10. Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.
The following tables present reportable segment financial information:
| Optum | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | UnitedHealthcare | Optum Health | Optum Insight | Optum Rx | Optum Eliminations | Optum | Corporate and Eliminations | Consolidated | ||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Services | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment and other income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Total operating costs (a) | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Total assets | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Purchases of property, equipment and capitalized software | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and Amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Services | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment and other income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Total operating costs (a) | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Total assets | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Purchases of property, equipment and capitalized software | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and Amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.
15
Table of Contents
| Optum | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | UnitedHealthcare | Optum Health | Optum Insight | Optum Rx | Optum Eliminations | Optum | Corporate and Eliminations | Consolidated | ||||||||||||||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Services | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment and other income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Total operating costs (a) | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Total assets | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Purchases of property, equipment and capitalized software | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and Amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Services | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | ||||||||||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment and other income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Total operating costs (a) | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Total assets | $ | $ | $ | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||
| Purchases of property, equipment and capitalized software | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and Amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.
16
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2024 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2024 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
•Optum Health;
•Optum Insight;
•Optum Rx; and
•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K and additional information on our segments can be found in this Item 2 and in Note 10 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Business Trends
Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings. We continually evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We seek to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical costs may impact both future pricing and benefit design, including for our individual exchange products in markets where we choose to remain, and result in shifts between product categories for our employer benefits. These potential changes, along with certain regulatory impacts, may result in decreased membership in future periods.
Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties,” and we have observed increased care patterns as discussed below in “Medical Cost Trends,” which may impact pricing and benefit design in future periods.
17
Table of Contents
Optum Health’s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate.
The Medicaid redetermination process has caused a timing mismatch between the health status of people served through Medicaid and state rate updates. Due to elevated care activity, specifically related to behavioral, pharmacy and home health, there continues to be a mismatch between the updated rates in 2025 and underlying member acuity. The funding and payment rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs. Additionally, we expect some Medicaid membership losses in 2026 as a result of early adoption of recent legislation.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. We have observed increased care patterns, more notably related to physician and outpatient care, and to a lesser extent inpatient and emergency room utilization, that are above what we expected and contemplated in our pricing and benefits design. We have also observed an increase in health care unit costs and in the intensity of services delivered, driven by increases in provider pricing and additional services bundled per visit. Additionally, the member profile of newly added patients under value-based care arrangements, people served in Medicare Advantage in markets where other have plans exited, and people served within our individual exchange business have contributed to increased medical costs. These trends may continue in future periods.
The Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in both increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums, altering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout the year.
We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we have elevated our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well below the industry forward medical cost trend, with the Final Notice for 2026 beginning to approach the industry forward medical cost trend. Additionally, increased medical costs in 2025, which are significantly above initial cost trend estimates, adds to the compounding impact of the previous multi-year rate shortfalls creating sustained pressure on the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health status and care resource needs, have resulted and will continue to result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select third quarter 2025 year-over-year operating comparisons to third quarter 2024 and other financial results.
•Consolidated revenues grew 12%, UnitedHealthcare revenues grew 16% and Optum revenues grew 8%.
•UnitedHealthcare served 795,000 more people, primarily driven by growth in Medicare Advantage.
•Consolidated earnings from operations of $4.3 billion compared to $8.7 billion last year, with 2025 impacted by elevated medical cost trend and 2024 impacted by the Change Healthcare cyberattack.
•Diluted earnings per common share were $2.59.
•Cash flows from operations for the nine months ended September 30, 2025 were $18.6 billion.
18
Table of Contents
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
| (in millions, except percentages and per share data) | Three Months Ended September 30, | Increase/ (Decrease) | Nine Months Ended September 30, | Increase/ (Decrease) | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 vs. 2024 | 2025 | 2024 | 2025 vs. 2024 | |||||||||||||||||||||||||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 88,979 | $ | 77,442 | $ | 11,537 | 15 | % | $ | 263,418 | $ | 232,327 | $ | 31,091 | 13 | % | ||||||||||||||||||||||||||||||||||
| Products | 13,296 | 12,631 | 665 | 5 | 39,896 | 36,751 | 3,145 | 9 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 9,754 | 9,104 | 650 | 7 | 27,765 | 26,742 | 1,023 | 4 | ||||||||||||||||||||||||||||||||||||||||||
| Investment and other income | 1,132 | 1,643 | (511) | (31) | 3,273 | 3,651 | (378) | (10) | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | 113,161 | 100,820 | 12,341 | 12 | 334,352 | 299,471 | 34,881 | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Operating costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical costs | 79,958 | 65,957 | 14,001 | 21 | 231,954 | 197,150 | 34,804 | 18 | ||||||||||||||||||||||||||||||||||||||||||
| Operating costs | 15,223 | 13,280 | 1,943 | 15 | 42,595 | 40,519 | 2,076 | 5 | ||||||||||||||||||||||||||||||||||||||||||
| Cost of products sold | 12,566 | 11,834 | 732 | 6 | 37,975 | 34,230 | 3,745 | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 1,099 | 1,041 | 58 | 6 | 3,244 | 3,058 | 186 | 6 | ||||||||||||||||||||||||||||||||||||||||||
| Total operating costs | 108,846 | 92,112 | 16,734 | 18 | 315,768 | 274,957 | 40,811 | 15 | ||||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | 4,315 | 8,708 | (4,393) | (50) | 18,584 | 24,514 | (5,930) | (24) | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | (1,003) | (1,074) | 71 | (7) | (3,028) | (2,903) | (125) | 4 | ||||||||||||||||||||||||||||||||||||||||||
| Loss on sale of subsidiary and subsidiaries held for sale | (83) | (20) | (63) | 315 | (139) | (8,331) | 8,192 | (98) | ||||||||||||||||||||||||||||||||||||||||||
| Earnings before income taxes | 3,229 | 7,614 | (4,385) | (58) | 15,417 | 13,280 | 2,137 | 16 | ||||||||||||||||||||||||||||||||||||||||||
| Provision for income taxes | (686) | (1,356) | 670 | (49) | (2,828) | (3,822) | 994 | (26) | ||||||||||||||||||||||||||||||||||||||||||
| Net earnings | 2,543 | 6,258 | (3,715) | (59) | 12,589 | 9,458 | 3,131 | 33 | ||||||||||||||||||||||||||||||||||||||||||
| Earnings attributable to noncontrolling interests | (195) | (203) | 8 | (4) | (543) | (596) | 53 | (9) | ||||||||||||||||||||||||||||||||||||||||||
| Net earnings attributable to UnitedHealth Group common shareholders | $ | 2,348 | $ | 6,055 | $ | (3,707) | (61) | % | $ | 12,046 | $ | 8,862 | $ | 3,184 | 36 | % | ||||||||||||||||||||||||||||||||||
| Diluted earnings per share attributable to UnitedHealth Group common shareholders | $ | 2.59 | $ | 6.51 | $ | (3.92) | $ | 13.21 | $ | 9.53 | $ | 3.68 | ||||||||||||||||||||||||||||||||||||||
| Medical care ratio (a) | 89.9 | % | 85.2 | % | 4.7 | % | 88.1 | % | 84.9 | % | 3.2 | % | ||||||||||||||||||||||||||||||||||||||
| Operating cost ratio | 13.5 | 13.2 | 0.3 | 12.7 | 13.5 | (0.8) | ||||||||||||||||||||||||||||||||||||||||||||
| Operating margin | 3.8 | 8.6 | (4.8) | 5.6 | 8.2 | (2.6) | ||||||||||||||||||||||||||||||||||||||||||||
| Tax rate | 21.2 | 17.8 | 3.4 | 18.3 | 28.8 | (10.5) | ||||||||||||||||||||||||||||||||||||||||||||
| Net earnings margin (b) | 2.1 | 6.0 | (3.9) | 3.6 | 3.0 | 0.6 | ||||||||||||||||||||||||||||||||||||||||||||
| Return on equity (c) | 9.9 | % | 26.3 | % | (16.4) | 17.0 | % | 13.2 | % | 3.8 | ||||||||||||||||||||||||||||||||||||||||
(a)Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
19
Table of Contents
2025 RESULTS OF OPERATIONS COMPARED TO 2024 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in people served through Medicare Advantage and those with higher acuity needs within Medicaid, growth at Optum Rx and pricing trends.
Medical Costs and MCR
Medical costs increased primarily due to the IRA-driven impacts on Medicare Part D plans, elevated medical cost trend and growth in people served through Medicare Advantage and those with higher acuity needs. The MCR increased as a result of the revenue effects of the Medicare funding reductions, elevated medical cost trend, the member profile of newly added patients under value-based care arrangements, the seasonal impacts of the IRA on Medicare Part D and the impacts of market morbidity changes on our individual exchange offerings. For the nine months ended September 30, 2025, the MCR also increased due to decreased favorable reserve development, partially offset by the incremental medical costs for accommodations made to care providers in 2024 as a result of the Change Healthcare cyberattack. The acceleration of anticipated future losses related to our individual exchange offerings recorded in the second quarter of 2025 decreased the MCR for the three months ended September 30, 2025 and increased the MCR for the nine months ended September 30, 2025.
Operating Cost Ratio
The operating cost ratio for the three months ended September 30, 2025, increased primarily due to decreased gains related to business portfolio refinement, business mix and investments to support future growth; partially offset by the revenue impacts of government programs, including the IRA-driven impacts on Medicare Part D plans and operating cost management. For the nine months ended September 30, 2025 the operating cost ratio decreased due to the revenue impacts of government programs, including the IRA-driven impacts on Medicare Part D plans; operating cost management and our direct response efforts to the Change Healthcare cyberattack in 2024; partially offset by business mix, investments to support future growth and decreased gains related to business portfolio refinement.
Tax Rate
The effective income tax rate decreased for the nine months ended September 30, 2025 due to non-deductible losses on the sale of subsidiary and subsidiaries held for sale in 2024.
Reportable Segments
See Note 10 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people, and pricing trends when comparing the metrics to revenue by segment.
20
Table of Contents
The following table presents a summary of the reportable segment financial information:
| Three Months Ended September 30, | Increase/ (Decrease) | Nine Months Ended September 30, | Increase/ (Decrease) | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except percentages) | 2025 | 2024 | 2025 vs. 2024 | 2025 | 2024 | 2025 vs. 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | $ | 87,070 | $ | 74,853 | $ | 12,217 | 16 | % | $ | 257,790 | $ | 224,076 | $ | 33,714 | 15 | % | ||||||||||||||||||||||||||||||||||
| Optum Health | 25,900 | 25,917 | (17) | — | 76,414 | 79,698 | (3,284) | (4) | ||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 4,915 | 4,931 | (16) | — | 14,373 | 13,976 | 397 | 3 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 39,679 | 34,207 | 5,472 | 16 | 113,270 | 97,457 | 15,813 | 16 | ||||||||||||||||||||||||||||||||||||||||||
| Optum eliminations | (1,317) | (1,130) | (187) | 17 | (3,770) | (3,275) | (495) | 15 | ||||||||||||||||||||||||||||||||||||||||||
| Optum | 69,177 | 63,925 | 5,252 | 8 | 200,287 | 187,856 | 12,431 | 7 | ||||||||||||||||||||||||||||||||||||||||||
| Eliminations | (43,086) | (37,958) | (5,128) | 14 | (123,725) | (112,461) | (11,264) | 10 | ||||||||||||||||||||||||||||||||||||||||||
| Consolidated revenues | $ | 113,161 | $ | 100,820 | $ | 12,341 | 12 | % | $ | 334,352 | $ | 299,471 | $ | 34,881 | 12 | % | ||||||||||||||||||||||||||||||||||
| Earnings from operations | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | $ | 1,805 | $ | 4,212 | $ | (2,407) | (57) | % | $ | 9,106 | $ | 12,611 | $ | (3,505) | (28) | % | ||||||||||||||||||||||||||||||||||
| Optum Health | 255 | 2,161 | (1,906) | (88) | 2,505 | 5,979 | (3,474) | (58) | ||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 706 | 791 | (85) | (11) | 2,665 | 1,827 | 838 | 46 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 1,549 | 1,544 | 5 | — | 4,308 | 4,097 | 211 | 5 | ||||||||||||||||||||||||||||||||||||||||||
| Optum | 2,510 | 4,496 | (1,986) | (44) | 9,478 | 11,903 | (2,425) | (20) | ||||||||||||||||||||||||||||||||||||||||||
| Consolidated earnings from operations | $ | 4,315 | $ | 8,708 | $ | (4,393) | (50) | % | $ | 18,584 | $ | 24,514 | $ | (5,930) | (24) | % | ||||||||||||||||||||||||||||||||||
| Operating margin | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | 2.1 | % | 5.6 | % | (3.5) | % | 3.5 | % | 5.6 | % | (2.1) | % | ||||||||||||||||||||||||||||||||||||||
| Optum Health | 1.0 | 8.3 | (7.3) | 3.3 | 7.5 | (4.2) | ||||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 14.4 | 16.0 | (1.6) | 18.5 | 13.1 | 5.4 | ||||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 3.9 | 4.5 | (0.6) | 3.8 | 4.2 | (0.4) | ||||||||||||||||||||||||||||||||||||||||||||
| Optum | 3.6 | 7.0 | (3.4) | 4.7 | 6.3 | (1.6) | ||||||||||||||||||||||||||||||||||||||||||||
| Consolidated operating margin | 3.8 | % | 8.6 | % | (4.8) | % | 5.6 | % | 8.2 | % | (2.6) | % | ||||||||||||||||||||||||||||||||||||||
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
| Three Months Ended September 30, | Increase/ (Decrease) | Nine Months Ended September 30, | Increase/ (Decrease) | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except percentages) | 2025 | 2024 | 2025 vs. 2024 | 2025 | 2024 | 2025 vs. 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Domestic | $ | 19,049 | $ | 18,985 | $ | 64 | — | % | $ | 57,065 | $ | 55,470 | $ | 1,595 | 3 | % | ||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Global | 826 | 769 | 57 | 7 | 2,427 | 2,892 | (465) | (16) | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Total | 19,875 | 19,754 | 121 | 1 | 59,492 | 58,362 | 1,130 | 2 | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Medicare & Retirement | 43,356 | 34,904 | 8,452 | 24 | 127,684 | 105,294 | 22,390 | 21 | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Community & State | 23,839 | 20,195 | 3,644 | 18 | 70,614 | 60,420 | 10,194 | 17 | ||||||||||||||||||||||||||||||||||||||||||
| Total UnitedHealthcare revenues | $ | 87,070 | $ | 74,853 | $ | 12,217 | 16 | % | $ | 257,790 | $ | 224,076 | $ | 33,714 | 15 | % | ||||||||||||||||||||||||||||||||||
21
Table of Contents
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
| September 30, | Increase/(Decrease) | |||||||||||||||||||||||||
| (in thousands, except percentages) | 2025 | 2024 | 2025 vs. 2024 | |||||||||||||||||||||||
| Commercial: | ||||||||||||||||||||||||||
| Risk-based | 8,440 | 8,900 | (460) | (5) | % | |||||||||||||||||||||
| Fee-based | 21,490 | 20,830 | 660 | 3 | ||||||||||||||||||||||
| Total Commercial | 29,930 | 29,730 | 200 | 1 | ||||||||||||||||||||||
| Medicare Advantage | 8,435 | 7,810 | 625 | 8 | ||||||||||||||||||||||
| Medicaid | 7,460 | 7,450 | 10 | — | ||||||||||||||||||||||
| Medicare Supplement (Standardized) | 4,300 | 4,340 | (40) | (1) | ||||||||||||||||||||||
| Total Community and Senior | 20,195 | 19,600 | 595 | 3 | ||||||||||||||||||||||
| Total UnitedHealthcare - Medical | 50,125 | 49,330 | 795 | 2 | % | |||||||||||||||||||||
| Supplemental Data: | ||||||||||||||||||||||||||
| Medicare Part D stand-alone | 2,795 | 3,055 | (260) | (9) | % | |||||||||||||||||||||
| South American businesses held for sale | 1,160 | 1,335 | (175) | (13) | % | |||||||||||||||||||||
UnitedHealthcare’s revenues increased due to the IRA-driven impacts on Medicare Part D plans and growth in the number of people served through Medicare Advantage, fee-based commercial offerings and those with higher acuity needs, partially offset by decreased people served through risk-based commercial offerings and Medicaid offerings.
Earnings from operations decreased primarily due to the impacts of Medicare Advantage funding reductions, elevated medical cost trend, the impacts of market morbidity changes on our individual exchange offerings and other write-offs and settlements. For the three months ended September 30, 2025, decreased earnings from operations was also due to the seasonal impact of the IRA on Medicare Part D. For the nine months ended September 30, 2025, decreased earnings from operations was partially offset by the seasonal impact of the IRA on Medicare Part D and the incremental medical costs for accommodations to support care providers in 2024 as a result of the Change Healthcare cyberattack. The acceleration of anticipated future losses related to our individual exchange offerings recorded in the second quarter of 2025 increased earnings from operations for the three months ended September 30, 2025 and decreased operating earnings for the nine months ended September 30, 2025.
Optum
Total revenues increased primarily due to growth at Optum Rx. For the nine months ended September 30, 2025, increased revenues were partially offset by Optum Health. Earnings from operations decreased due to Optum Health, partially offset by the impacts of the Change Healthcare cyberattack in 2024. The results by segment were as follows:
Optum Health
Revenues at Optum Health decreased primarily due to the conversion of risk-based contracts, Medicare Advantage funding reductions and the profile of members served, partially offset by growth in patients served under value-based arrangements. Earnings from operations decreased due to Medicare Advantage funding reductions, the member profile of newly added patients under value-based care arrangements, elevated medical cost trends and decreased gains related to business portfolio refinement, partially offset by cost management initiatives. For the three months ended September 30, 2025 decreased earnings from operations was also due to lower investment income, partially offset by decreased contractual settlements. For the nine months ended September 30, 2025, decreased earnings from operations was also partially offset by the incremental medical costs for accommodations to support care providers in 2024 as a result of the Change Healthcare cyberattack. Optum Health served approximately 96 million people and 104 million people as of September 30, 2025 and September 30, 2024, respectively.
Optum Insight
Revenues and earnings from operations at Optum Insight decreased for the three months ended September 30, 2025 due to lower volumes within business services, partially offset by growth in technology services and decreased impacts related to the Change Healthcare cyberattack. Revenues and earnings from operations increased for the nine months ended September 30, 2025 due to decreased impacts related to the Change Healthcare cyberattack and growth in technology services, partially offset by lower volumes within business services.
22
Table of Contents
Optum Rx
Revenues at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Earnings from operations increased due to the factors impacting revenue and operating cost efficiencies, partially offset by decreased investment income. Optum Rx fulfilled 414 million and 407 million adjusted scripts in the third quarters of 2025 and 2024, respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
| Nine Months Ended September 30, | Increase/(Decrease) | |||||||||||||||||||
| (in millions) | 2025 | 2024 | 2025 vs. 2024 | |||||||||||||||||
| Sources of cash: | ||||||||||||||||||||
| Cash provided by operating activities | $ | 18,589 | $ | 21,835 | $ | (3,246) | ||||||||||||||
| Issuances of short-term borrowings and long-term debt, net of repayments | 2,438 | 15,120 | (12,682) | |||||||||||||||||
| Proceeds from common stock issuances | 803 | 1,611 | (808) | |||||||||||||||||
| Sales and maturities of investments, net of purchases | 1,657 | 1,852 | (195) | |||||||||||||||||
| Repayments of care provider loans - cyberattack | 1,543 | 3,189 | (1,646) | |||||||||||||||||
| Total sources of cash | 25,030 | 43,607 | (18,577) | |||||||||||||||||
| Uses of cash: | ||||||||||||||||||||
| Common stock repurchases | (5,545) | (4,028) | (1,517) | |||||||||||||||||
| Cash paid for acquisitions and other transactions, net of cash assumed | (4,436) | (11,674) | 7,238 | |||||||||||||||||
| Purchases of property, equipment and capitalized software | (2,674) | (2,587) | (87) | |||||||||||||||||
| Cash dividends paid | (5,914) | (5,601) | (313) | |||||||||||||||||
| Loans to care providers - cyberattack | — | (8,904) | 8,904 | |||||||||||||||||
| Customer funds administered | (1,792) | (1,059) | (733) | |||||||||||||||||
| Other | (2,767) | (2,497) | (270) | |||||||||||||||||
| Total uses of cash | (23,128) | (36,350) | 13,222 | |||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 25 | (30) | 55 | |||||||||||||||||
| Increase in cash and cash equivalents, including cash within businesses held for sale | $ | 1,927 | $ | 7,227 | $ | (5,300) | ||||||||||||||
| Less: net increase in cash within businesses held for sale | (29) | (254) | 225 | |||||||||||||||||
| Net increase in cash and cash equivalents | $ | 1,898 | $ | 6,973 | $ | (5,075) | ||||||||||||||
2025 Cash Flows Compared to 2024 Cash Flows
Decreased cash flows provided by operating activities were driven by decreased net earnings, partially offset by changes in working capital accounts and the impacts of the Change Healthcare cyberattack in 2024. Other significant changes in sources or uses of cash year-over-year included net repayments of loans to care providers in response to the Change Healthcare cyberattack and decreased cash paid for acquisitions and other transactions, offset by decreased net issuances of short-term borrowings and long-term debt, increased share repurchases, decreased proceeds from common stock issuances and decreased customer funds administered.
Financial Condition
As of September 30, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of $76.3 billion included approximately $27.2 billion of cash and cash equivalents (of which $1.2 billion was available for general corporate use), $46.8 billion of debt securities and $2.2 billion of investments in marketable equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.3 years and a weighted-average credit rating of “Double A” as of September 30, 2025. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
23
Table of Contents
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2024 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K. During the nine months ended September 30, 2025, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K. As of September 30, 2025, we were in compliance with the various covenants under our bank credit facilities.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.
Credit Ratings. Our credit ratings as of September 30, 2025 were as follows:
| Moody’s | S&P Global | Fitch | A.M. Best | ||||||||||||||||||||||||||||||||||||||||||||
| Ratings | Outlook | Ratings | Outlook | Ratings | Outlook | Ratings | Outlook | ||||||||||||||||||||||||||||||||||||||||
| Senior unsecured debt | A2 | Negative | A+ | Negative | A | Negative | A- | Stable | |||||||||||||||||||||||||||||||||||||||
| Commercial paper | P-1 | n/a | A-1 | n/a | F1 | n/a | AMB-1 | n/a | |||||||||||||||||||||||||||||||||||||||
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Regulatory Capital. As a result of an increased MCR impacting our regulated insurance and HMO subsidiaries, the specified levels of required statutory capital required to be maintained are expected to increase. We entered into various agreements with reinsurers that could limit our risk of loss under certain circumstances, thus reducing our capital and surplus requirements. These agreements do not qualify for reinsurance accounting and are therefore accounted for under deposit accounting.
While we continue to maintain significant levels of excess statutory capital in our subsidiaries, the amount of dividends our subsidiaries are able to pay to their parent companies during the remainder of 2025 will be impacted. During the nine months ended September 30, 2025, our domestic insurance and HMO subsidiaries paid their parent companies dividends, net of capital infusions, of $841 million.
Share Repurchase Program. During the nine months ended September 30, 2025, we repurchased approximately 12.1 million shares of common stock at an average price of $454.82 per share. As of September 30, 2025, we had Board of Directors’ authorization to purchase up to 21.0 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
Dividends. In June 2025, our Board of Directors increased our quarterly cash dividend to an annual rate of $8.84 compared to $8.40 per share, which we had paid since June 2024. For more information on our dividend, see Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K.
24
Table of Contents
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal actions concerning our participation in the Medicare program; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the sale of our remaining operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
25
Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of September 30, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
| September 30, 2025 | ||||||||||||||||||||||||||
| Increase (Decrease) in Market Interest Rate | Investment Income Per Annum | Interest Expense Per Annum | Fair Value of Financial Assets | Fair Value of Financial Liabilities | ||||||||||||||||||||||
| 2 % | $ | 728 | $ | 576 | $ | (4,249) | $ | (9,525) | ||||||||||||||||||
| 1 | 364 | 288 | (2,170) | (5,160) | ||||||||||||||||||||||
| (1) | (364) | (273) | 2,210 | 6,284 | ||||||||||||||||||||||
| (2) | (728) | (544) | 4,421 | 13,949 | ||||||||||||||||||||||
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2025. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2025.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26
Table of Contents
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2024 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2024 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2024 10-K.
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
There were no repurchases of the Company’s common stock during the three months ended September 30, 2025. As of September 30, 2025, the Company had 21 million shares remaining available under its share repurchase authorization.
ITEM 5. OTHER INFORMATION
Trading Arrangements
During the quarter ended September 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted terminated
27
Table of Contents
ITEM 6. EXHIBITS**
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A/A filed on July 1, 2015) | |||||||
3.2 | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26, 2021) | |||||||
4.1 | Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April 28, 2023) | |||||||
4.2 | Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008) | |||||||
4.3 | Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April 24, 2023) | |||||||
*10.1 | Employment Agreement, effective as of September 2, 2025, between United HealthCare Services, Inc. and Wayne S. DeVeydt (incorporated by reference to Exhibit 10.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on July 31, 2025). | |||||||
31.1 | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||||||
32.1 | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |||||||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101). | |||||||
________________
| * | Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K. | |||||||
| ** | Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request. | |||||||
28
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ STEPHEN HEMSLEY | Chair and Chief Executive Officer (principal executive officer) | Dated: | October 28, 2025 | |||||||||||
| Stephen Hemsley | ||||||||||||||
/s/ WAYNE DEVEYDT | Chief Financial Officer (principal financial officer) | Dated: | October 28, 2025 | |||||||||||
| Wayne DeVeydt | ||||||||||||||
/s/ THOMAS ROOS | Senior Vice President and Chief Accounting Officer (principal accounting officer) | Dated: | October 28, 2025 | |||||||||||
| Thomas Roos | ||||||||||||||
29
FAQ
How did UnitedHealth (UNH) perform in Q3 2025?
Total revenues were $113.2 billion (+12% YoY) and diluted EPS was $2.59 as higher medical costs reduced margins.
What drove UnitedHealth’s revenue growth in Q3 2025?
Growth was led by Medicare Advantage membership increases and higher volumes at Optum Rx.
Why did UNH margins compress this quarter?
The medical care ratio rose to 89.9% due to Medicare funding reductions, elevated utilization, and IRA-driven Part D seasonality.
How did the segments perform for UNH?
UnitedHealthcare revenue +16%; Optum revenue +8% with Optum Rx +16%. Optum Health saw profit pressure.
What were UNH’s operating cash flows in 2025 year-to-date?
Cash flows from operations were $18.6 billion for the nine months ended September 30, 2025.
How many more people did UnitedHealthcare serve?
795,000 more year over year, primarily in Medicare Advantage.
Unitedhealth Gp
NYSE:UNH
UNH Rankings
UNH Latest News
Oct 28, 2025
UnitedHealth Group Reports Third Quarter 2025 Results and Raises Full Year 2025 Earnings Outlook
Oct 1, 2025
UnitedHealthcare’s 2026 Medicare Advantage Plans Deliver Value, Access and Consumer Choice
Sep 15, 2025
UnitedHealth Group Announces Earnings Release Date
UNH Latest SEC Filings
Oct 28, 2025
[8-K] UNITEDHEALTH GROUP INC Reports Material Event
UNH Stock Data
333.14B
897.80M
0.82%
86.64%
1.32%
Healthcare Plans
Hospital & Medical Service Plans
United States
EDEN PRAIRIE